Premium
Microarray and Pathway Analysis of Prostate Cancer Tumors Treated with Andrographolide
Author(s) -
ForestierRoman Ingrid Samari,
Sánchez María,
Rohena Krizia,
OrtizZuazaga Humberto,
MartínezFerrer Magaly
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.766.12
Subject(s) - andrographolide , andrographis paniculata , prostate cancer , cancer , cancer research , cell cycle , microarray , microarray analysis techniques , tissue microarray , biology , medicine , gene expression , pharmacology , gene , pathology , genetics , alternative medicine
Prostate cancer is the most frequently diagnosed non‐cutaneous cancer and the second cause of cancer‐related deaths in American men. Andrographolide, a labdane diterpenoid that is a component of the medicinal plant Andrographis paniculata , has been reported to have a wide range of biological activities including anticarcinogenic properties. In previous studies, we found that Andrographolide inhibits cell growth, cell migration and tumor growth in prostate cancer. The objective of this study is to examine the gene expression profile of prostate cancer tumors treated with Andrographolide. For this, we conducted microarray analysis of tumors treated with Andrographolide 10 mg/kg and their vehicle. Tumors were developed using a xenograft model in which the prostates of SCID mice were injected with 22RV1, and mice were treated three times per week with Andrographolide 10 mg/kg. Tumor tissues were collected and snap frozen. Gene expression was identified and analyzed using the Affymetrix GeneChip® Human Gene 2.0 array. Microarray studies showed that a total of 537 genes were upregulated and 138 were downregulated in tumors treated with Andrographolide 10 mg/kg when compared to their vehicle. By using Ingenuity Pathway Analysis (IPA) we found that Andrographolide 10 mg/kg altered molecular and cellular functions including “DNA Replication, Recombination and Repair”, “Cell Cycle”, “Cellular Compromise”, “Cellular Assembly and Organization” and “Post‐Translational Modification”. Understanding these biological pathways and networks is essential to determine possible targets of Andrographolide in prostate cancer. Support or Funding Information NIH K01 CA140711 NIH RCMI #8G12MD007600 Seed Funds from University of Puerto Rico Comprehensive Cancer Center U54CA096297